Pediatric type III dyslipidaemia may present as a transient condition that resolves in adulthood, allowing for the discontinuation of lipid-lowering therapy.
Answers are grounded in this paper and cite their sources.
May indicate transient pediatric type III dyslipidaemia; leaves open whether therapy discontinuation is safe without prospective confirmation.
An 11-year-old girl presented with palmar and tuberoeruptive xanthomas, and elevated triglycerides and total cholesterol levels. She had an apolipoprotein E2/E2 genotype. A diagnosis of type III dyslipidaemia was made and the patient started on niacin, fenofibrate and salmon oil. At age 18, her lipid levels were well controlled with fenofibrate once weekly. At age 21, the fenofibrate was discontinued and her lipid profile has been normal for the last 4 years. This case history may be consistent with a transient dyslipidaemia.
No takes yet. Share an insight, caveat, or question.
Sarwal et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: